Summary of Study ST001665

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001070. The data can be accessed directly via it's Project DOI: 10.21228/M8D12Q This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST001665
Study Title	Branched-chain alpha-ketoacids are preferentially reaminated and activate protein synthesis in the rat heart
Study Summary	Branched-chain amino acids (BCAA) and their cognate α-ketoacids (BCKA) are elevated in an array of cardiometabolic diseases. Here we demonstrate that the major metabolic fate of uniformly-13C-labeled α-ketoisovalerate ([U-13C]KIV) in the heart is reamination to valine. Activation of cardiac branched-chain α-ketoacid dehydrogenase (BCKDH) by treatment with the BCKDH kinase inhibitor, BT2, does not impede the strong flux of [U-13C]KIV to valine.
Institute	Duke University
Last Name	Walejko
First Name	Jacquelyn
Address	300 N Duke St
Email	jacquelyn.walejko@duke.edu
Phone	9194792304
Submit Date	2021-01-26
Analysis Type Detail	GC-MS
Release Date	2021-02-17
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001755
Treatment Summary:	All heart perfusions underwent an initial 15-minute equilibration period with Krebs Ringer bicarbonate buffer containing 119 mM NaCl, 4.8 mM KCl, 2.6 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, and 0.05 mM L-carnitine at a flow rate of 12 ml/minute. After the equilibrium period, hearts were perfused for 30 minutes with 3% BSA, 100 µU/mL insulin, 0.4 mM palmitate, physiologic concentrations of amino acids, and either DMSO (Veh), BT2, or LY3351337.

Treatment ID:

TR001755

Treatment Summary:

All heart perfusions underwent an initial 15-minute equilibration period with Krebs Ringer bicarbonate buffer containing 119 mM NaCl, 4.8 mM KCl, 2.6 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, and 0.05 mM L-carnitine at a flow rate of 12 ml/minute. After the equilibrium period, hearts were perfused for 30 minutes with 3% BSA, 100 µU/mL insulin, 0.4 mM palmitate, physiologic concentrations of amino acids, and either DMSO (Veh), BT2, or LY3351337.